Search / Trial NCT00001105

The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of March 02, 2024

Completed

Keywords

Antibodies, Monoclonal Aids Related Complex Immunization, Passive

Description

Early in the course of HIV infection, the primary humoral immune response appears to be highly strain specific and to be directed at a hypervariable portion of the viral gp120. The F105 human monoclonal antibody reacts with the CD4 binding region of gp120 and has been shown to neutralize the IIIB, SF2, and MN strains of HIV at concentrations readily achievable in humans. In Part A, three cohorts of four patients each receive a single intravenous (IV) injection of F105 human monoclonal antibody at 1 of 3 doses. The IV catheter will remain in the patient's arm for 12 hours after injection fo...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • PART B ONLY. Allowed:
  • Concomitant AZT or other antiretroviral drugs if patient is on a stable dose of such therapy within 3 months prior to study entry.
  • Patients must have:
  • Documented HIV-1 infection.
  • CD4 count 200 - 500 cells/mm3 (Part A) or <= 400 cells/mm3 (Part B, per amendment).
  • No diagnosis of AIDS (Part A only, per amendment).
  • Life expectancy of at least 6 months.
  • Part B patients only (per amendment):
  • Primary (viral) isolates sensitive to F105 antibody using the yield reduction assay currently under development by ACTG, determined within 15-90 days prior to study entry.
  • Plasma viremia by qualitative plasma culture.
  • NO active opportunistic infection within 6 weeks prior to drawing of first isolate.
  • NO AIDS-related malignancy other than minimal Kaposi's sarcoma.
  • Prior Medication:
  • Allowed:
  • Prior AZT or other nucleoside antiviral agents.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Evidence of active renal disease as manifested by sediment containing red or white cell casts.
  • Concurrent Treatment:
  • Excluded:
  • Red cell transfusions administered to maintain hemoglobin at acceptable level or alleviate symptoms of anemia.
  • Prior Medication:
  • Excluded within 6 weeks prior to study entry:
  • Intravenous gamma globulin.
  • Chemotherapy.
  • Corticosteroids.
  • Other experimental therapy.
  • EXCLUDED IN ALL PATIENTS:
  • Immunosuppressive treatments, cytokine therapy, or biologic response modifiers not included in this study, including interferons or adjuvant treatment for chronic and severe fungal infections such as cryptococcal meningitis.
  • Intravenous gamma globulin.
  • Chemotherapy.
  • Corticosteroids.
  • Other experimental therapy.
  • G-CSF, GM-CSF, or erythropoietin.
  • EXCLUDED IN PART A ONLY:
  • Drugs known to enhance or block metabolism of other drugs.
  • EXCLUDED IN PART B ONLY:
  • AZT or other antiretroviral drugs IF INITIATED during or within 1 month after completion of study.
  • Active alcohol or drug abuse that may compromise ability to comply with study requirements.

Attachments

readout_NCT00001105_2024-03-02.pdf

4.5 MB

NCT00001105_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Boston, Massachusetts, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0